Opus Genetics partner Viatris files sNDA with FDA for presbyopia treatment

Opus Genetics, Inc.

Viatris filed sNDA for Phentolamine Ophthalmic Solution 0.75% to treat presbyopia.
sNDA supported by positive VEGA-3 Phase 3 results confirming efficacy, safety, durability.
No assurance FDA will accept sNDA or complete review on anticipated timeline.

item 8.01

Opus Genetics, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-25-046187

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.